4-Methylthioamphetamine

4-Methylthioamphetamine
Legal status
Legal status	BR: Class F2 (Prohibited psychotropics); CA: Schedule I; DE: Anlage I (Authorized scientific use only); UK: Class A; US: Schedule I; UN: Psychotropic Schedule I;
Identifiers
	IUPAC name 1-[4-(Methylsulfanyl)phenyl]propan-2-amine;
CAS Number	14116-06-4 (R/S); 1030831-15-2 (R); 943816-61-3 (S);
PubChem CID	151900;
ChemSpider	133883 ;
UNII	6JP2T8KXTR;
KEGG	C22804 ;
ChEMBL	ChEMBL6467 ;
CompTox Dashboard (EPA)	DTXSID90894854 ;
Chemical and physical data
Formula	C10H15NS
Molar mass	181.30 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES NC(C)CC(C=C1)=CC=C1SC;
	InChI InChI=1S/C10H15NS/c1-8(11)7-9-3-5-10(12-2)6-4-9/h3-6,8H,7,11H2,1-2H3 ; Key:OLEWMKVPSUCNLG-UHFFFAOYSA-N ;
	(what is this?) (verify)

4-Methylthioamphetamine (4-MTA) is a designer drug of the substituted amphetamine class developed in the 1990s by a team led by David E. Nichols, an American pharmacologist and medical chemist, at Purdue University. It acts as a non-neurotoxic highly selective serotonin releasing agent (SSRA) in animals. 4-MTA is the methylthio derivative of amphetamine.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.